Back D, et al. - In view of the limitations in using direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in patients with neuropsychiatric disorders due to worries over lower treatment adherence and interactions between medications, researchers conducted an integrated analysis of registrational studies using the pangenotypic DAA regimen of glecaprevir and pibrentasvir (G/P) to report on adherence, efficacy, safety and patient-reported outcomes (PROs). Based on medical history and/or co-medications, they classified whether patients had a psychiatric disorder. They identified 2,522 patients who were receiving G/P; among these, a psychiatric disorder was noted in 789 (31%), with depression (64%; 506/789) and anxiety disorders (27%; 216/789) being the most common diagnoses. As per outcomes, patients with chronic HCV infection and psychiatric disorders showed high efficacy with G/P treatment, with good-tolerability and high adherence rates.